Profiles of patients with non-receptor pain treated with pregabalin Case report
Article Sidebar
Published:
Nov 30, 2025
Keywords:
pregabalin, non-nociceptive pain, generalized anxiety disorder, epilepsy
Main Article Content
Abstract
This article discusses the use of pregabalin in the treatment of non-nociceptive pain, particularly neuropathic and nociplastic pain, as well as its role in the treatment of generalized anxiety disorder and epilepsy. The drug’s mechanism of action and clinical efficacy are presented using two case studies of patients with different pain profiles and comorbidities. Pregabalin, with its good safety profile and documented efficacy, is an important therapeutic tool in the treatment of complex pain syndromes, especially in patients with multimorbidity.
Article Details
How to Cite
Białecka , M. (2025). Profiles of patients with non-receptor pain treated with pregabalin. Medycyna Faktow (J EBM), 18(3(68), 466-472. https://doi.org/10.24292/01.MF.0325.19
Issue
Section
Articles
Copyright by Medical Education. All rights reserved.
References
1. Stahl SM, Porreca F, Taylor CP et al. The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities? Trends Pharmacol Sci. 2013; 34: 332-9.
2. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007; 73(2): 137-50.
3. Rometsch C, Martin A, Junne F et al. Chronic pain in European adult populations: a systematic review of prevalence and associated clinical features. Pain. 2025; 166(4): 719-31. http://doi.org/10.1097/j.pain.0000000000003406.
4. Nijs J, Kosek E, Chiarotto A et al. Nociceptive, neuropathic, or nociplastic low back pain? The low back pain phenotyping (BACPAP) consortium’s international and multidisciplinary consensus recommendations. Lancet Rheumatol. 2024; 6(3): e178-88. http://doi.org/10.1016/S2665-9913(23)00324-7.
5. Soliman N, Moisset X, Ferraro MC et al.; NeuPSIG Review Update Study Group. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol. 2025; 24(5): 413-28. http://doi.org/10.1016/S1474-4422(25)00068-7.
6. Finnerup NB, Attal N, Haroutounian S et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and metaanalysis. Lancet Neurol. 2015; 14(2): 162-73. http://doi.org/10.1016/S1474-4422(14)70251-0.
7. Davari M, Amani B, Amani B et al. Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: A systematic review and meta-analysis. Korean J Pain. 2020; 33(1): 3-12. http://doi.org/10.3344/kjp.2020.33.1.3.
8. Allam AK, Sharma H, Larkin MB et al. Trigeminal Neuralgia: Diagnosis and Treatment. Neurol Clin. 2023; 41(1): 107-21. http://doi.org/10.1016/j.ncl.2022.09.001.
9. Fagan HA, Baldwin DS. Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions. Expert Rev Neurother. 2023; 23(6): 535-48.
10. Stein DJ, Baldwin DS, Baldinetti F et al. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol. 2008; 18(6): 422-30.
11. Rejdak K, Mazurkiewicz-Bełdzińska M, Błaszczyk B et al. Diagnostyka i leczenie padaczki – rekomendacje Sekcji Padaczki Polskiego Towarzystwa Neurologicznego. Polski Przegląd Neurologiczny 2022; 18(4): 201-19.
12. Bockbrader HN, Wesche D, Miller R et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010; 49(10): 661-9.
13. Raouf M, Bettinger J, Wegrzyn EE et al. Pharmacotherapeutic Management of Neuropathic Pain in End-Stage Renal Disease. Kidney Dis (Basel). 2020; 6(3): 157-67. http://doi.org/10.1159/000504299.
14. Terminology. International Association for the Study of Pain (IASP).
15. Bułdyś K, Górnicki T, Kałka D et al. What Do We Know about Nociplastic Pain? Healthcare (Basel). 2023; 11(12): 1794. http://doi.org/10.3390/healthcare11121794.
16. Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med. 2011; 123(5): 134-42.
17. Araszkiewicz A, Bandurska-Stankiewicz E, Borys S et al. Standards of Care in Diabetes. The position of Diabetes Poland – 2024. Current Topics in Diabetes. 2023; 3(3-4): 1-348. https://doi.org/10.5114/ctd/183052.
18. Tong C, Zhengyao Z, Mei L et al. Pregabalin and Gabapentin in Patients with Spinal Cord Injury-Related Neuropathic Pain: A Network Meta-Analysis. Pain Ther. 2021; 10(2): 1497-509.
19. Winkelman JW, Berkowski JA, DelRosso LM et al. Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2025; 21(1): 137-52.
20. Atış G, Bilir Kaya B. Pregabalin treatment of three cases with brachioradial pruritus. Dermatol Ther. 2017; 30(2). http://doi.org/10.1111/dth.12459.
21. Guilleminault L, Grassin-Delyle S, Mazzone SB. Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough. Drugs. 2024; 84(7): 763-77. http://doi.org/10.1007/s40265-024-02047-y.
22. Drug Scheduling & Classifications (List of Schedule I-V Controlled rugs).
2. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007; 73(2): 137-50.
3. Rometsch C, Martin A, Junne F et al. Chronic pain in European adult populations: a systematic review of prevalence and associated clinical features. Pain. 2025; 166(4): 719-31. http://doi.org/10.1097/j.pain.0000000000003406.
4. Nijs J, Kosek E, Chiarotto A et al. Nociceptive, neuropathic, or nociplastic low back pain? The low back pain phenotyping (BACPAP) consortium’s international and multidisciplinary consensus recommendations. Lancet Rheumatol. 2024; 6(3): e178-88. http://doi.org/10.1016/S2665-9913(23)00324-7.
5. Soliman N, Moisset X, Ferraro MC et al.; NeuPSIG Review Update Study Group. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol. 2025; 24(5): 413-28. http://doi.org/10.1016/S1474-4422(25)00068-7.
6. Finnerup NB, Attal N, Haroutounian S et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and metaanalysis. Lancet Neurol. 2015; 14(2): 162-73. http://doi.org/10.1016/S1474-4422(14)70251-0.
7. Davari M, Amani B, Amani B et al. Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: A systematic review and meta-analysis. Korean J Pain. 2020; 33(1): 3-12. http://doi.org/10.3344/kjp.2020.33.1.3.
8. Allam AK, Sharma H, Larkin MB et al. Trigeminal Neuralgia: Diagnosis and Treatment. Neurol Clin. 2023; 41(1): 107-21. http://doi.org/10.1016/j.ncl.2022.09.001.
9. Fagan HA, Baldwin DS. Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions. Expert Rev Neurother. 2023; 23(6): 535-48.
10. Stein DJ, Baldwin DS, Baldinetti F et al. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol. 2008; 18(6): 422-30.
11. Rejdak K, Mazurkiewicz-Bełdzińska M, Błaszczyk B et al. Diagnostyka i leczenie padaczki – rekomendacje Sekcji Padaczki Polskiego Towarzystwa Neurologicznego. Polski Przegląd Neurologiczny 2022; 18(4): 201-19.
12. Bockbrader HN, Wesche D, Miller R et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010; 49(10): 661-9.
13. Raouf M, Bettinger J, Wegrzyn EE et al. Pharmacotherapeutic Management of Neuropathic Pain in End-Stage Renal Disease. Kidney Dis (Basel). 2020; 6(3): 157-67. http://doi.org/10.1159/000504299.
14. Terminology. International Association for the Study of Pain (IASP).
15. Bułdyś K, Górnicki T, Kałka D et al. What Do We Know about Nociplastic Pain? Healthcare (Basel). 2023; 11(12): 1794. http://doi.org/10.3390/healthcare11121794.
16. Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med. 2011; 123(5): 134-42.
17. Araszkiewicz A, Bandurska-Stankiewicz E, Borys S et al. Standards of Care in Diabetes. The position of Diabetes Poland – 2024. Current Topics in Diabetes. 2023; 3(3-4): 1-348. https://doi.org/10.5114/ctd/183052.
18. Tong C, Zhengyao Z, Mei L et al. Pregabalin and Gabapentin in Patients with Spinal Cord Injury-Related Neuropathic Pain: A Network Meta-Analysis. Pain Ther. 2021; 10(2): 1497-509.
19. Winkelman JW, Berkowski JA, DelRosso LM et al. Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2025; 21(1): 137-52.
20. Atış G, Bilir Kaya B. Pregabalin treatment of three cases with brachioradial pruritus. Dermatol Ther. 2017; 30(2). http://doi.org/10.1111/dth.12459.
21. Guilleminault L, Grassin-Delyle S, Mazzone SB. Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough. Drugs. 2024; 84(7): 763-77. http://doi.org/10.1007/s40265-024-02047-y.
22. Drug Scheduling & Classifications (List of Schedule I-V Controlled rugs).